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High-resolution ultrasound for the study of target
joints in rheumatoid arthritis
To the Editor:
Conventional radiography remains the “gold standard”
for the evaluation of joint damage and its progression in
rheumatoid arthritis (RA), but changes may not be evident
radiographically until late in the disease course (1). Magnetic
resonance imaging (MRI) has been used to study patients with
early RA, but high cost and lack of standardization limit its use
(2). Several studies have now shown that high-resolution
ultrasound (US) of the metacarpophalangeal (MCP) joints can
be very informative in the evaluation of RA of various
durations (3–5). Erosions have been visualized in selected
hand joints (second MCP) and foot joints (fifth metatarsopha-
lageal [MTP]) (5). In fact, detection of more erosions per joint
and per patient with US as compared with radiography was
demonstrated by Wakefield et al in a recent study reported in
Arthritis & Rheumatism (3).
The present pilot study was undertaken to assess the
feasibility of performing US in selected (target) joints of
patients with RA, and to determine if this technique offers
additional information beyond that obtained with conventional
radiography. MRI was chosen as a comparator method be-
cause of its high sensitivity. Our Institutional Review Board
approved this study.
Ten unselected patients with RA according to the
criteria of the American College of Rheumatology (formerly,
the American Rheumatism Association) (6) and 5 healthy
volunteers who, as a group, were of comparable age (mean 45
years), sex (80% women), and ethnicity (80% white) with the
patients were studied. The duration of RA was 2 years in 2
patients, 3–5 years in 5, and 5 years in 3. Six of the 10 patients
were positive for IgM rheumatoid factor. Five of the 10 were
receiving a disease-modifying antirheumatic drug (methotrex-
ate in 4 of the 5); 3 other patients were receiving anti–tumor
necrosis factor therapy.
Joints selected for US imaging included the second and
fifth MCP joints and the fifth MTP joints. These joints were
selected on the basis of their likelihood of early involvement in
RA as well as their easy accessibility with the US probe. The
first MTP joints, not considered targets for involvement early
in the course of RA, were also examined because of their easy
accessibility with the US probe.
Conventional radiographs of the hands/wrists and feet
were obtained. These included 3 views (anteroposterior, lat-
eral, and oblique) obtained using standard techniques (Kilo-
volt peak 54, milliampere-second 2.5, fine detail film-screen
combination). Coronal T1-weighted MR images of the hands
and feet were obtained using a 1.5T body scanner (Signa; GE,
Milwaukee, WI), dedicated extremity coils, and the following
parameters: repetition time 500 msec, echo time 15 msec,
256  192 matrix, 3 mm thickness with 0.5 mm gap, field of
view 20 cm). Finally, US of the joints as noted above was
performed by one of us (RL-B), using 10–15 MHz high-
resolution linear array transducers with small footprints. Indi-
vidual scanning parameters were optimized for musculoskele-
tal detail for the US machines utilized (Sequoia; Accuson,
Mountain View, CA and HDI 3000; Advanced Technologies
Laboratories, Bothell, WA). In each subject, the 3 studies were
performed between a few hours and 10 days apart.
Radiography was considered the gold standard and
used to calculate the sensitivity, specificity, and predictive
value of US. Radiographic films from patients and controls
were coded and blinded and were read independently by 2
experienced rheumatologists (GSA, LWM) for erosions in the
same joints imaged by US; the final erosion count recorded per
joint and per patient was the average from the 2 readers. US
and MR images from patients and controls were mixed and
then read for erosions by a fellowship-trained musculoskeletal
radiologist (RL-B) with experience in sonography. An erosion
by sonography was defined as a cortical defect 2 mm in width
with an irregular floor seen in longitudinal and transverse
planes. An erosion by MRI was defined as a focus of decreased
T1 marrow signal occurring in a juxtaarticular or subchondral
distribution.
Table 1 shows the comparison of the findings with the
3 imaging modalities as well as the sensitivity, specificity, and
overall accuracy of US and MRI compared with radiography.
As in the study by Wakefield et al (3), all erosions found by
radiography were also identified by US and MRI. US was
superior to conventional radiography in the identification of
erosions; moreover, it was superior to MRI in some instances,
perhaps due to volume averaging of pixels given the technique
used. Erosions detected by US, but not by MRI, were all small
(2–3 mm). US, with in-plane axial resolution 1 mm at such
superficial depth for the transducers used, would be better able
to resolve such small cortical defects.
We have shown that erosions can be identified by US
in patients with RA of various durations and that the study can
be performed in a busy outpatient clinic. The time to complete
the study (and its costs) can be reduced substantially if only
joints that are typically affected early in the course of the
disease and/or whose surface is easily accessible with the US
probe are examined. These joints include the second and fifth
MCP joints and the fifth MTP joints. Of interest, no additional
information was derived from the assessment of the first MTP
joints, since no erosions were detected in these joints. US of
target joints in RA patients meets the Outcome Measures in
Rheumatology Clinical Trials filter requirements (truth dis-
crimination and feasibility) (7). Demonstrating the presence of
erosions early in the course of the disease, before radiographic
findings are apparent, may allow the clinician to initiate more
aggressive therapy, which in the long term may result in better
patient outcomes. This is quite important considering the new
therapies now available for RA (8–10).
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The conclusions discussed in the interesting letter by
Alarcón et al, albeit derived from a small number of patients,
confirm the findings of ourselves and others that high-
frequency US is an accurate and reliable method of detecting
bone erosions in patients with RA (1,2). In Alarcón and
colleagues’ study, despite 3 views being obtained (compared
with a single posteroanterior view in our study), plain radiog-
raphy remained less sensitive than US.
The authors comment on the advantage of scanning,
“selected joints” as a time- and cost-saving exercise. Scanning
only a few joints may theoretically be time saving; however, in
clinical practice, we find that the most time-consuming step is
patient positioning and undressing. A full assessment of all of
the MCP joints by an experienced sonographer takes only 5
minutes. Furthermore, US also provides information on soft
tissue involvement (synovitis and tenosynovitis), as well as
providing valuable insight into the true extent of disease by
demonstrating subclinical involvement. While US has a greater
sensitivity for detecting erosions on second and fifth MCP
joints and fifth MTP joints where there is better transducer
access, MRI studies (3,4) suggest that synovitis affects all joints
approximately equally, and therefore, important clinical dis-
ease may be missed if scanning is limited to only a few areas.
Alarcón et al also highlight the ability of US to detect
small erosions. This may be particularly important in early RA.
In our study of 100 RA patients (1), 90% of small erosions in
the early-disease group were small, (defined as 2 mm),
compared with 63% in the longer-duration group. This ex-
plains why conventional radiography is an insensitive tech-
nique for detection of erosions in patients with early RA.
Although MRI is a potentially powerful technique, its
use is currently limited in many centers, due to availability and
cost issues. In our center, US is used extensively in the clinic
but has not replaced radiography for the assessment of bone
damage. Rather, it is used as a complementary tool with a
particular role in evaluating patients who are at high risk for
inflammatory arthritis in whom radiographic findings are
normal, or for reexamining nonspecific lesions detected on
radiography.
Richard J. Wakefield, MRCP
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Radiography 8 3 – – –
MRI 14 7 100 65 76
US 19 8 100 45 61
* Values are for 10 patients with rheumatoid arthritis; in healthy controls, no erosions were detected with any of the three imaging modalities.
† Compared with radiography.
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Can very high-dose anti–tumor necrosis factor
blockade at onset of rheumatoid arthritis produce
long-term remission?
To the Editor:
The combination of methotrexate and infliximab, a
chimeric monoclonal anti–tumor necrosis factor  (TNF)
antibody, has been shown to be very effective in reducing the
signs and symptoms of rheumatoid arthritis (RA) (1,2). There
are theoretical reasons why early use of anti-TNF might
interrupt monocyte/macrophage function, producing long-
lasting clinical benefits (3). If these theories are correct, then
early use of high-dose remission-induction therapy could be-
come standard treatment. Currently, some clinically important
questions about this therapeutic approach need to be ad-
dressed. First, is nonresponsiveness to anti-TNF attributable to
insufficient doses, and, if so, can poor clinical response be
overcome by use of an adequately high dose? Second, can use
of very high-dose anti-TNF therapy early in the course of
disease have a profound influence on outcome, allowing
drug-free remission to be achieved? To answer these ques-
tions, we conducted a pilot study using high-dose infliximab,
with reinduction if no remission occurred. State-of-the-art
imaging modalities were used.
The study group comprised 5 patients with newly
diagnosed inflammatory arthritis. All patients fulfilled the
American College of Rheumatology (ACR; formerly, the
American Rheumatism Association) criteria for RA (4) and
had not previously received any disease-modifying antirheu-
matic drugs (DMARDs). Other inclusion criteria were RA of
12 months duration and 3 poor prognostic criteria (based
on sex, C-reactive protein [CRP] level, rheumatoid factor
[RF], shared epitope, and Health Assessment Questionnaire
score [5]). The protocol was approved by the local ethics
committee, and all patients gave informed consent.
Methotrexate therapy (increasing to a maximum dos-
age of 15 mg/week) began at baseline. Patients received
infliximab, 10 mg/kg, at weeks 0, 2, 6, and 10. If remission had
not occurred by week 12, they received a repeat, “reinduction”
regimen. Standard clinical and laboratory outcome evaluations
were performed at all time points. Magnetic resonance imag-
ing (MRI) scans and high-resolution ultrasonography of the
dominant hand (2nd to 5th metacarpophalangeal joints) were
performed at weeks 0, 12, and 48, as previously described (6).
The MRI sequences and scoring method were consistent with
recent expert recommendations (7). Bone densitometry scans
(spine, both femoral necks, and hands) were also performed at
0 and 48 weeks.
The mean duration of symptoms of the 5 patients was
7.3 months. Four patients were female, 4 had a positive family
history of RA, 4 were RF-positive, and all 5 possessed the
shared epitope (previously known as HLA–DR4 and DR1). At
baseline, 1 patient had erosions on conventional radiographs
of the hands and feet. The clinical and imaging outcomes are
presented in Table 1. After the initial administration of 4
infusions of high-dose infliximab (3 times higher than the
conventional dose), 1 patient was in remission, 3 showed highly
significant improvement (2 ACR 70% response and 1 ACR
50% response [8]), and 1 demonstrated no improvement. The
3 patients who underwent reinduction of high-dose infliximab
(1 patient did not undergo reinduction because of a previous
infusion reaction) did not achieve further remission or im-
provement. In particular, the patient who showed no improve-
ment following initial therapy also showed no response to
reinduction, and that patient’s serum CRP level increased after
treatment. No patient achieved drug-free remission.
Imaging modalities demonstrated a reduction in global
synovitis (see Figure 1) in all 4 patients who responded
clinically but not in the nonresponding patient, in whom the
degree of synovitis was unaltered by therapy. The reduction in
synovitis was accompanied by a dramatic reduction in bone
Table 1. Clinical and imaging outcomes*
Outcome measure
Week 0 Week 12
Week 48,
respondersResponders Non-responders Responders Non-responders
Early morning stiffness, minutes 105 300 0 300 10
Tender joint count 12 33 3 26 7.5
Swollen joint count 8.8 9 1.3 13 1.3
Patient’s global assessment on 100-
mm VAS
62 80 6 40 11
C-reactive protein, mg/ml 46 48 6 41 10
Health Assessment Questionnaire,
raw score
11.8 19 3 15 2.8
MRI synovitis global score† 7 7 3 6 5
MRI bone edema sites‡ 2.5 0 0.5 0 0.5
Ultrasound synovitis global score† 4 2 1.5 3 2.8
* Values for the responders (n  4) are the means. The nonresponding patient was withdrawn from the study at 6 months, with results similar to
those at week 12, except for C-reactive protein (125 mg/ml). VAS  visual analog scale; MRI  magnetic resonance imaging.
† Sum of 4 metacarpophalangeal joints, each scored 0–3.
‡ Sum of sites demonstrating bone edema, counted as proximal and distal for each joint.
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edema as seen on MRI, and no joints with reduced synovitis
according to MRI scans developed new erosions. Bone densi-
tometry in the 4 responding patients demonstrated a small loss
over 48 weeks compared with the nonresponder (average loss
1.6% versus 3.4%).
This unique experiment examined the effect of very
high-dose TNF blockade at the time of presentation followed
by reinduction in RA patients who did not achieve remission.
We specifically included patients with a poor prognosis, who
may be candidates for more aggressive initial therapy. Results
of this study answered the questions initially posed. One of 5
patients did not respond to therapy, but the variable clinical
response clearly was not attributable to an insufficient dose of
infliximab. Repeat induction with high-dose therapy did not
produce any greater response in the partial responders, and
the nonresponder had no improvement whatsoever. A more
likely explanation for the variable response may be the known
heterogeneity of synovial TNF expression observed in patients
with RA (9).
With respect to the disparity between nonresponse and
radiologic damage, imaging showed a close correlation be-
tween response and reduction of synovitis in the imaged joints.
Among patients who had a good response to therapy, synovitis
was reduced, and no further joint damage occurred. The
nonresponding patient had no reduction in synovitis and was
withdrawn from the study at 6 months, after failed reinduction.
Prevention of damage is clearly relevant to long-term
outcome. All previous studies of conventional DMARDs have
indicated that bone loss, as measured by bone densitometry,
continues despite aggressive therapy. Although this bone loss
was slowed in our patients, it was not completely abolished,
perhaps because true remission was not achieved in all cases.
Finally, although a good response was seen in all but 1 patient
(nonresponder), a more profound effect on the disease, allow-
ing drug-free remission, was not seen. All patients had contin-
ued disease activity that required treatment with anti-TNF. It
is therefore clear that the forces driving RA were not stopped
by early administration of high-dose anti-TNF therapy.
We are grateful to Schering-Plough UK for supplying infliximab.
Philip G. Conaghan, MBBS, FRACP
Mark A. Quinn, MBBS, MRCP
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Figure 1. Magnetic resonance imaging of the metacarpophalangeal
joints. Axial T1-weighted spin-echo post-gadolinium views of the same
patient (responder) at baseline (A) and week 14 (B), showing dramatic





The concept that patients with early RA may exhibit a
universal and long-lasting remission following a limited course
of high-dose anti-TNF therapy, unlike that observed in pub-
lished trials of infliximab therapy, is worth exploring. The small
study reported by Conaghan et al does not lend support to such
a concept and suggests that in a small subset of patients TNF
may not be a pivotal regulator of the inflammatory response.
We have learned a great deal about the pathogenesis
of RA, and specifically the role of TNF in the mechanism of
disease, from interventional studies using infliximab (1,2).
Occasionally, an RA patient does not express TNF in synovial
tissues, and a correlation between the absence of TNF and
lack of response to infliximab has been previously observed (3).
However, we must exercise caution in concluding that re-
sponses measured by ACR improvement criteria necessarily
reflect the outcome of all aspects of rheumatoid pathology. We
should note that in the anti-Tumor Necrosis Factor Trial in
Rheumatoid Arthritis with Concomitant Therapy, assessment
of serial radiographs of hands and feet demonstrated that
progression of joint space narrowing (cartilage loss) and bone
erosions was inhibited by infliximab, but not placebo, in ACR
nonresponders (4).
The relationship between synovitis and cartilage, bone,
and tendon damage, as evaluated by powerful new imaging
techniques such as those used in the study by Conaghan and
colleagues, should clarify whether invasive pannus and synovi-
tis are causally interrelated or may be independently regulated.
If the latter is the case, a dissociation between the ACR
response criteria, which are sensitive to change in synovitis,
and measurement of structural damage, may be observed in
some patients. Whether use of anti-TNF therapy would be
clinically justified in such circumstances is, of course, debat-
able.
Ravinder N. Maini, MBBChir, FRCP, FMedSci
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Morbidity not increased in rheumatoid arthritis
patient with profound lymphopenia following CD4
monoclonal antibody therapy: comment on the article
by Isaacs et al
To the Editor:
We read with interest the article by Isaacs et al (Isaacs
JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, et
al. Morbidity and mortality in rheumatoid arthritis patients
with prolonged and profound therapy-induced lymphopenia.
Arthritis Rheum 2001;44:1998–2008), in which they report that
although profound and long-lasting lymphopenia occurs fol-
lowing treatment of rheumatoid arthritis (RA) with antilym-
phocyte monoclonal antibody, this therapy is not associated
with substantially excessive mortality nor with an unusual
range of infection during a medium-term followup period. In
addition, the authors stress the dissimilarity between this
cohort of lymphopenic post-immunotherapy patients and
equivalently lymphopenic patients with human immunodefi-
ciency virus (HIV) infection.
At present, we are providing care for a 71-year-old
woman who has had RA for more than 20 years. She had been
treated with multiple agents, alone or in combination, includ-
ing nonsteroidal antiinflammatory drugs, methotrexate, gold,
prednisone, and D-penicillamine. She remained symptomatic
until 1997, when she was given an intravenous CD4 monoclo-
nal antibody twice weekly for a total of 4 weeks. She had an
excellent clinical response, with complete resolution of her
symptoms. Remission, however, lasted only 4 months. The
patient has remained symptomatic with symmetric synovitis
involving multiple joints, including the metacarpophalangeals,
proximal interphalangeals, wrists, elbows, and knees, despite
aggressive therapy for the past 30 months with cyclosporine,
tumor necrosis factor  (TNF) inhibitors, and monthly pulses
of solumedrol. As expected, following initiation of CD4 mono-
clonal antibody therapy, her CD4 cell count decreased signif-
icantly (Table 1) and remains below normal levels 55 months
later.
Our patient has not exhibited any unusual and/or
opportunistic infection despite her profound and long-lasting
decreased CD4 cell count and the added therapy with
cyclosporine, pulse methylprednisolone, or TNF inhibitor.
This, as discussed by Isaacs and colleagues, contrasts with what
occurs in HIV-infected patients. As in HIV patients, however,
active synovitis does occur, and this finding is somewhat
distressing considering that CD4 cells are thought to play a
key role in the pathogenesis of RA (Espinoza LR, Aguilar JL,
Berman A, Gutierrez F, Vasey FB, Germain BF. Rheumatic
manifestations associated with human immunodeficiency virus
infection. Arthritis Rheum 1989;32:1615–22). This is a relevant
issue that deserves further consideration and is most likely
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We thank Menon and colleagues for their interest in
our work and for sharing their own data with us. We do not
believe that the presence of synovitis in lymphopenic RA
patients denigrates the role of CD4 T cells in this disease.
First, and as we discussed, very few memory T cells are needed
to initiate a recall immune response. Whereas this fact may in
part explain the resistance to infection observed in our pa-
tients, it also makes eradication of their RA less likely. Thus, in
order for a depleting therapy to permanently ablate a T
cell–driven disease, it presumably would need to kill the vast
majority of T cells that have become sensitized to autoantigen.
In the absence of such an effect, the disease is likely to recur.
Conversely, achieving such an effect would require use of more
potent or more prolonged lymphocytotoxic therapy, which may
then result in compromised immune defenses. Second, it is
now clear that not all autoreactive T cells are pathogenic, but
that some are actively regulatory (1). It is unlikely that a
depleting therapy, whether targeted at CD52 or CD4 (both of
which are expressed on regulatory T cells), would specifically
spare them. In this regard, lymphocytotoxic therapy theoreti-
cally could worsen autoreactivity if the balance of regulation-
to-effector function were altered unfavorably.
Fortunately, cellular ablation is not necessary for con-
trol of autoaggressive T cells. In animal models, noncytotoxic
therapies targeted at antigens such as CD4 or CD8 appear to
empower potent immunoregulatory processes within the recip-
ient and, in that sense, offer more benefit than that of the
equivalent cytotoxic therapies (2). Although this phenomenon
has yet to be adequately explained at the molecular level, it
provides for long-term control of autoreactivity (3). To date,
such therapies have not provided impressive disease control in
humans. Few have been truly noncytotoxic, however, and as we
have previously noted, the doses used in patients, on a
weight-for-weight basis, fall far short of those needed to
control autoreactivity in animals (4). Furthermore, at present
we lack appropriate markers with which to monitor T cell–
targeted therapy in humans (5).
In summary, despite the recurrence of synovitis in
lymphopenic RA patients, we continue to believe that T
cell–targeted therapy may play a role in disease control. In fact,
relapsed RA in recipients of CAMPATH-1H appears to be
more readily controlled with conventional disease-modifying
antirheumatic drugs, even those that were previously ineffec-
tive (Isaacs JD, et al: unpublished observations). We recently
made similar observations following autologous stem cell
transplantation for RA (6), suggesting that lymphocytotoxic
therapies may, in fact, be immunomodulatory. Our current
efforts, however, are focused on the use of high doses of
nondepleting monoclonal antibodies targeted at a variety of
cell surface antigens, and on identification of appropriate T
cell markers with which to monitor such therapy.
John D. Isaacs, PhD, FRCP
University of Leeds
Leeds, UK
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DNASE I mutation and systemic lupus erythematosus
in a Spanish population: comment on the article by
Tew et al
To the Editor:
Tew et al (1) did not find any particular mutation in the
DNASE I gene when studying 18 systemic lupus erythematosus
(SLE) patients. Their interest was based on the fact that many
studies have indeed found a link between DNASE I and the
development of SLE. Actually, serum DNase I activity in
different organic fluids has been shown to be low both in
lupus-prone mice and SLE patients (2,3). Napirei et al (4)
further corroborated this fact by generating DNASE
I–deficient mice that developed clear features of SLE. And















CD4, % 33 48 7 7 8 15 23
Helper/suppressor cell ratio 1.06 1.5 0.14 0.15 0.17 0.32 0.47
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even 2 of 20 SLE patients were recently found to be heterozy-
gous for a nonsense mutation in 1 exon of the DNASE I gene
(5); besides showing decreased DNase I activity, these patients
had high IgG anti-nucleosome antibodies. The mutation was
found in exon 2, and a single A3T transversion took place in
the signal peptide coding region; it led to the formation of a
stop codon, which gave rise to a predicted truncated protein
that contained just 4 nucleotides.
To ascertain the true role of this mutation, we evalu-
ated the presence of such a mutation in a Spanish SLE
population. We analyzed 108 SLE patients (14 men, 94
women) and 100 healthy control subjects (38 men, 62 women).
All the patients fulfilled the revised criteria of the American
College of Rheumatology for the classification of SLE (6).
Genomic DNA was prepared from peripheral blood mono-
nuclear cells. A 428-bp DNA fragment was amplified by
polymerase chain reaction (PCR) and digested with Nsp I
since, as seen by Yasutomo et al (5), the base change would
generate a new cleavage site for this enzyme. Thus, if the
mutation had been found to be present, we would have
expected to obtain 2 digested products, 1 of 160 bp and
another of 268 bp. We even sequenced the 428-bp PCR
product of 5 patients to confirm that it was actually the desired
fragment.
To make sure that our digestion reaction was perform-
ing well, we also amplified a 428-bp DNA fragment down-
stream of the region of interest, which happened to contain 2
restriction sites for Nsp I. In this case, 3 fragments of the
following sizes were to be generated: 164 bp, 140 bp, and 124
bp. As seen in Figure 1, neither patients nor controls had the
mutation. Therefore, this particular nucleotide change does
not appear to be associated with SLE in the Spanish popula-
tion.
Yasutomo et al (5) just studied 20 SLE patients, and
although the sample size was smaller than ours, they found the
mutation in 10% of the cases. Ethnic differences may obviously
account for the disagreement. In accordance with our results
are those reported recently by Tew et al (1), in which they did
not find the mutation in any of the 18 American SLE patients.
It would be interesting to check if other mutations on the
DNASE I gene exist and whether they are more frequent in
Caucasians than in Japanese SLE patients when considering
larger cohorts. If the low DNase I serum activity shown by
other authors was confirmed in our SLE patients and no other
mutations were found, this would open the possibility for the
existence of a defective transcriptional or posttranslational
mechanism of the enzyme. Tew et al (1) indeed suggested the
latter when they found that none of the 13 SLE patients
differed in DNASE I transcript levels from the 7 healthy
controls.
On the other hand, DNAse II activity has been shown
to be decreased in neutrophils from peripheral blood in
patients with SLE (7). Consequently, other nuclease enzymes
could also be blamed for the noncomplete degradation of
extracellular DNA in the blood of SLE patients.
We believe that the rate of clearance of extracellular
plasma DNA has important implications for the pathologic
mechanism of SLE. SLE is mainly characterized by the pres-
ence of pathogenic autoantibodies to nucleoprotein antigens,
with double-stranded DNA (dsDNA) being the most impor-
tant. There are substantial data to support the fact that the
autoimmune response developed by these patients is antigen
driven. Therefore, a noncomplete clearing of cellular debris
could trigger the manufacturing of autoantibodies, including
anti-dsDNA antibodies, as a result of the lack of DNA
degradation.
Nevertheless, this is actually a very complex disease,
and believing that only 1 enzyme could be responsible for
protection against autoimmunity seems to be too simple. The
results of our study do not support the hypothesis of a
particular described single mutation being the cause of the
abnormality. Further research is needed for us to ascertain
whether other genes are involved in the insufficient clearance
of DNA in lupus patients.
Supported by a grant (FIS 00/0882) from the Fondo de Investi-
gación Sanitaria of Spain.
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Figure 1. Restriction enzyme digestion analysis of polymerase chain
reaction products. Lanes 1–2  digestion control (before and after Nsp
I digestion, respectively); lanes 3–10  Nsp I digestion of genomic
DNA amplified both from systemic lupus erythematosus patients
(lanes 3–8) and controls (lanes 9–10); lane 11  negative control
(water); M  100-bp molecular weight marker DNA; 2.5% agarose gel
stained with SYBR Green I.
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We thank Dr. Balada and colleagues for their interest
in our report (1). Their analysis of Spanish SLE patients for the
DNASE I exon 2 mutation described by Yasumoto et al (2) is
in agreement with the deoxyribonuclease I gene (DNASE I)
sequencing results in our United States cohort (1). One
possibility that may account for the difference that Balada and
colleagues have pointed out is ethnic heterogeneity, or a
mutation on a different part of the DNASE I gene. The latter
cannot be formally ruled out in this instance, since Balada et al
only tested for 1 mutation in 1 of 9 exons of DNASE I in their
cohort. Another consideration is age. All of the SLE patients
we studied had adult-onset disease. The exon 2 mutation
described by Yasumoto et al (2) occurred in 2 young girls, ages
13 and 17 years, raising the possibility that mutations in
DNASE I may be more prevalent in childhood-onset SLE.
Six known genetic polymorphisms account for the
various isoforms of human DNase I (3–5), but there are no
significant differences in serum DNase activity among the 3
major isoforms (DNASE1*1, *2, and *3) (6). Thus, while
diminished serum DNase activity is a common finding among
SLE patients (7), a DNASE I mutation that accounts for this
phenotype in the majority of SLE patients has yet to be widely
reported, suggesting that other contributing factors exist.
As a followup to our earlier report (1), we ascertained
serum DNase activity in patients with SLE due to homozygous
deficiencies of C4 and C1r. Complete deficiencies of C4 and
C1r (and other genes in the early classical pathway of comple-
ment) are very rare, but the prevalence of SLE in these
patients is extremely high, 75% and 57%, respectively (8).
Because these mutations confer a high relative risk for SLE,
Figure 1. Box plot of serum DNase activity in 4 homozygous,
complement-deficient patients. DNase activity was determined in
triplicate, as previously described (1,12), except that 2 mM CaCl2 was
added to the final reaction buffer to increase the sensitivity of the assay
because DNase I is an Mg2/Ca2-dependent nuclease (13). Serum
DNase activity in 4 totally complement-deficient lupus patients, 2
white male siblings (patients 1 and 2) and a white female systemic
lupus erythematosus (SLE) patient (patient 3), was completely C4A
and C4B deficient, while 1 African American male SLE patient
(patient 4) was totally C1r deficient. Patient 1 was diagnosed with SLE
at age 7, and clinical manifestations included severe chronic cutaneous
lupus (CCL) polyarthritis, leukopenia/thrombocytopenia, and digital
vasculitis. Antinuclear antibodies (ANA) and anti-Sm and -RNP were
positive, but all other lupus antibodies were negative. Patient 2 also
developed CCL, proven by skin biopsy at an early age, but had no other
end organ involvement over 30 years of followup (ANA, anti–double-
stranded DNA, and other lupus autoantibodies were consistently
negative). Homozygous C4A- and C4B-deficient status for patients 1
and 2 was demonstrated as previously described (14,15). Clinical and
serologic details on patient 3 were reported earlier (16). Patient 4
developed severe CCL at age 3 months. A renal biopsy showed
mesangial glomerulonephritis with focal proliferative changes and IgA
and C3 deposition. Serum complement studies showed that the total
hemolytic component was not detectable, C1q was 40 g/ml (60% of
normal), C1r was not detectable, and C1s was 22 g/ml (61% of
normal). Levels of C2, C3, C4, C5, C6, C7, C8, C9, C3b inactivator,
-1H globulin, C1 inhibitor, and C1s were all increased but properdin
levels were normal. A second renal biopsy at age 18 showed diffuse
proliferative glomerulonephritis with deposition of IgG, IgM, IgA, C3,
and C1q, but not C4 by immunofluorescence. Fifteen SLE patients
without a total complement component deficiency and 15 healthy race-
and sex-matched controls were also studied. Except for C4-deficient
patient 2 with CCL, all the SLE patients fulfilled the American College
of Rheumatology criteria for SLE (17). E  individual controls for
SLE patients; F  parents of patients 1 and 2 (both parents were
healthy and ANA negative);   C4-deficient patients; ‚  C1r-
deficient patient; horizontal line in each box  median; boxed areas 
25th and 75th percentiles; error bars  10th and 90th percentiles.
Pairwise comparisons between groups were made using the Mann-
Whitney U test. The parents of patients 1 and 2 are shown for
comparison only and were not included in the comparative analyses.
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they are likely to be single-gene diseases. Low serum DNase
activity in these patients would be consistent with the idea that
factors other than DNASE I mutations alone affect serum
DNase activity, since the odds of an individual inheriting 2 rare
gene mutations would be exceedingly low. Four such patients
(3 complete C4 and 1 complete C1r deficient) were studied.
The number of patients studied is small, reflecting the very low
frequency of homozygous C4 and C1r mutations in the popu-
lation. The results show that serum DNase activity in patients
with SLE due to genetic defects in the classical pathway of
complement is not significantly different from that in the usual
SLE patients (Figure 1). Both groups had serum DNase
activity that was significantly diminished compared with that of
healthy controls.
We agree with Dr. Balada and colleagues that defects
in the ability to clear extracellular DNA likely contribute to the
etiopathogenesis of SLE. While mutations in DNASE I could
be an occasional, but rare, cause of SLE in humans, the
etiology of the low serum DNase activity in SLE is undoubt-
edly complex. Thus far, the data suggest that in most SLE
patients this phenomenon cannot be explained solely by
DNASE I mutations alone. DNASE I transcript levels could be
influenced by alternative splicing (9) or messenger RNA
stability (10) (although there was no evidence of differences in
splicing in our earlier study [1]). There is the potential for
epistatic interaction with other genes or, alternatively, enzyme
activity could be modulated by posttranslational events such as
glycosylation, or by microenvironments particular to specific
tissues (6,11). Further investigation will be required to deter-
mine if any of these processes downstream from gene tran-
scription are affected in SLE patients, or if defects in other
endonucleases are present.
Monty B. Tew, MD
Randall W. Johnson, MD
John D. Reveille, MD
Filemon K. Tan, MD, PhD
University of Texas Health Science Center
Houston, TX
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Call for a trial of Lyprinol, an over-the-counter
5-lipoxygenase inhibitor: comment on the article by
Kowal-Bielecka et al
To the Editor:
In their discussion of dermal overexpression of
5-lipoxygenase (5-LOX) in systemic sclerosis (SSc), Kowal-
Bielecka et al (1) remind us that disease-modifying therapies
for SSc are far from satisfactory. With the demise of benoxa-
profen and zileuton, there is not very much to offer in the way
of 5-LOX inhibitors. Nonspecific antioxidants (e.g., nordihy-
droguiaretic acid) have been studied in asthma, without too
much success. Each of the alternative strategies for reducing
the deleterious effects of leukotrienes, namely curtailing the
supply of arachidonate, the 5-LOX substrate, (with cortico-
steroids) or antagonizing leukotriene receptors (e.g., with
montelukast, zafirlukast), presents problems of side effects or
specificity.
An alternative 5-LOX inhibitor is Lyprinol, an over-
the-counter nutritional supplement that is a lipid extract from
the green-lipped mussel (Perna canaliculus). These mussels are
farmed in pristine waters (Marlborough Sounds) in New
Zealand’s South Island. Studies to date indicate that Lyprinol
is a 5-LOX inhibitor (2,3), has antiarthritic activity without
gastric side effects in rats and humans (2,4), and is effective in
asthma (5). Particularly valuable is its synergy with low-dose
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corticosteroids (e.g., prednisone, dexamethasone) in amelio-
rating asthma (6) or experimental fibrosis in rats (7). It would
seem timely to conduct a trial of Lyprinol in a few patients with
SSc, perhaps in combination with a steroid.
The mussel from which Lyprinol is derived has been a
traditional staple of the diet of the New Zealand Maori people.
Advantages of using the lipid extract, Lyprinol, a 20 mussel
concentrate, are that it is prepared from fresh-frozen, stabi-
lized mussels, it is salt-free, and nonallergenic, and it has no
solvent residues (liquified carbon dioxide is being used under
supercritical conditions to extract it). There currently are
distributors of Lyprinol in the US.
Michael W. Whitehouse, DPhil
Princess Alexandra Hospital
Woolloongabba, Qld, Australia
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We thank Dr. Whitehouse for his comments on our
study. The up-regulation of 5-LOX in skin biopsy specimens
from SSc patients compared with those from healthy controls,
along with reports about positive effects of LOX inhibitors in
fibrotic animal models, led us to the conclusion that inhibition
of the 5-LOX pathway might be a treatment option in SSc. This
hypothesis is further supported by recent data from our
laboratories showing that leukotriene B4, a product of the
5-LOX pathway, is also up-regulated in bronchoalveolar lavage
fluids from patients with SSc. Thus, treatment with inhibitors
of the 5-LOX pathway not only might have favorable effects on
the progression of skin fibrosis but also might influence the
pathogenesis of scleroderma lung disease.
In general, the biologic action of leukotrienes can be
blocked by selective inhibitors of 5-LOX (e.g., zileuton),
leukotriene receptor antagonists (e.g., montelukast and
zafirlukast), inhibitors of the 5-LOX activating protein (e.g.,
MK-591), and newly developed dual inhibitors, which are able
to block both cyclooxygenase and LOX pathways. Lyprinol is
not a specific 5-LOX inhibitor but has been suggested to exert
its antiinflammatory action in part via inhibition of the 5-LOX
pathways.
Several points should be considered before trials with
5-LOX inhibitors are started in patients with SSc. As outlined
in our report, there was considerable basal synthesis of 5-LOX
in the skin of healthy controls, indicating that this pathway
might be involved in physiologic processes. In addition, the SSc
group was heterogeneous in that many patients showed a
strong up-regulation of 5-LOX, while some others showed
expression of 5-LOX in the range of that of the healthy
controls. Because only the former group is likely to benefit
from inhibition of 5-LOX, these patients should be selected for
early trials. Certainly, the American College of Rheumatology
guidelines for clinical trials in SSc should be considered (White
B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn
JH, et al. Guidelines for clinical trials in systemic sclerosis








Congenital fascial dystrophy, a new scleroderma-like
genetic disease with limitation of joint mobility:
comment on the clinical image presented by Di Rocco
To the Editor:
Congenital fascial dystrophy, described by Di Rocco as
stiff skin syndrome (1), is a scleroderma-like syndrome that is
virtually unknown to rheumatologists, even though patients
with this condition are usually receiving treatment at rheuma-
tology institutions. This autosomal recessive disease is often
identified as scleroderma or sclerodermatomyositis because of
indurations of the soft tissues, contractures, and limitation of
joint mobility. Because of such misidentification, patients may
be subjected to aggressive and harmful therapy.
In 1971, Esterly and McKusick (2) described stiff skin
syndrome, a condition recognized as a localized connective
tissue disorder or limited mucopolysaccharidosis without mu-
copolysacchariduria. Subsequently, highly heterogeneous dis-
ease processes and various scleroderma-like dysmorphic syn-
dromes were reported under this name (3–6). In single cases,
Alcian blue deposits were observed between collagen fibers
(2,7–9), which favored some relationship with muco-
polysaccharidosis.
Our group has reported cases in which patients display
stony-hard generalized indurations of the soft tissues, with no
visceral involvement and no immunologic or vascular abnor-
malities (10,11). Frequently, these changes are already notice-
able on the buttocks and thighs during the first year of life, with
progressive involvement of the trunk and limbs. Because of
contractures of the limbs, patients have characteristic tiptoe
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posture and difficulty walking (Figure 1). Sharp demarcation
of the sclerotic tissues at the inguinal channel is also charac-
teristic; thus, the vessels and nerves pass freely into the limbs,
causing no vascular or nervous system derangement. The
general condition of patients is quite satisfactory. The only
life-threatening aspect is tightening of the thoracic fascia,
which may result in underdevelopment of the thorax and
pulmonary insufficiency in older patients.
All patients that we described as having congenital
fascial dystrophy (10,11) had markedly thickened fascia, with
no inflammatory infiltrates (Figure 2A). However, electron
microscopic evaluation of the fascia disclosed giant (up to 300
nm) amianthoid-like fibrils, some of which were not ade-
quately linked to form definite collagen fibrils (10,11) (Figure
2B). Our most recent immunohistochemical and electron
microscopic studies of fascia and cultured fibroblasts from
patients with congenital fascial dystrophy showed the absence
of collagen III, the presence of a large amount of myofibro-
blasts, and overproduction of spectrin and the filamentous
form of collagen VI (12). This would suggest that the abnormal
composition of the fascia depends on modulation of fibroblasts
into myofibroblasts capable of producing spectrin and long-
spacing collagen.
Of special practical interest is the occurrence of abor-
tive forms of congenital fascial dystrophy that mimic deep
morphea or deep linear scleroderma (13,14). Such cases are
most frequently thought to be scleroderma and are treated as
such, with no effect. In our experience, patients with congenital
fascial dystrophy can improve considerably if rehabilitation is
started early after onset and is continued throughout life. An
intensive rehabilitation program may prevent severe pulmo-
nary side effects. We have patients who, in spite of persistent
stony-hard indurations, are sportsmen, and 3 of our female
patients have given birth to normal babies. We believe that
congenital fascial dystrophy, although related to a highly
heterogeneous group of diseases referred to as stiff skin
syndrome, is a distinct entity in terms of pathology, composi-
tion of fascia, course, and outcome.
Stefania Jablonska, MD
Warsaw School of Medicine
Warsaw, Poland
1. Di Rocco M. Stiff skin syndrome [clinical image]. Arthritis Rheum
2000;43:1542.
Figure 1. Congenital fascial dystrophy. The patient has stony-hard,
profound indurations involving the skin and deeper tissues of the
whole body, which are especially pronounced on the thighs and
buttocks. The tiptoe posture, caused by contractures of the lower limbs
and limitation of mobility of the knees and hips, is characteristic. The
thorax is thinned, in contrast to the well-developed shoulder muscles.
Figure 2. Fascia from a patient with congenital fascial dystrophy. A,
Verhoeff-van Gieson–stained section, showing marked thickening of
the fascia (4 times normal). No inflammatory infiltrates were observed,
and the muscle was not involved (magnification  60). B, Electron
microscopic image, showing amianthoid-like collagen fibrils with major
and minor periodicity. A bundle of aggregated microfibrils runs
parallel to the collagen fibrils. Some giant fibrils showed divisions into
2 or 3 branches (magnification  50,000).
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Cognitive function in fibromyalgia: comment on the
article by Park et al
To the Editor:
Physicians recognize memory complaints to be fre-
quent in patients with fibromyalgia. It is not clear, however,
how the recent study by Park et al (1) did more than allow
those patients who chose to reveal their concerns to do so in a
quantifiable manner. Thus, if a patient tells you he or she
cannot repeatedly lift a 10-pound weight because of pain, then
on testing it would be no surprise to find this result. There are
techniques to assess consistency of effort, and where these are
included, the results of previous studies (2,3) suggest that the
failure of memory is more likely a failure of effort. Results of
our own very recent study (4) suggested that this effort failure
correlated well with patients’ perceptions and certification for
disability. Given this background, surely this aspect of proof of
effort should be included in any similar study; otherwise, one
will merely find that patients validate their predictions of their
memory by their responses.
A. S. Russell, FRCP(C)
Roger Gervais, PhD, CPsych
University of Alberta
Edmonton, Alberta, Canada
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Drs. Russell and Gervais suggest that our findings of
significant cognitive deficits in patients with fibromyalgia (FM)
can be attributed to a failure of effort on the part of FM
patients. There are two lines of evidence to suggest that this is
not the basis for our findings. First, perhaps the most sensitive
measure of cognitive function is speed of processing (Park DC,
Lautenschlager G, Hedden T, Davidson N, Smith AD, Smith
P. Visuo-spatial and verbal memory across the lifespan. Psy-
chol Aging. In press), and this is a measure on which FM
patients performed better than older adults and as fast as
young adults. The finding of intact speed of processing, but
impaired working memory and long-term memory, does not
accord with a motivational explanation, since one would expect
to see a general decrement across tasks rather than selective
decrements specific to certain tasks. Second, to address effort
and fatigue issues, our study was designed to have 3 blocked
segments of tasks, each block of which included measures of
speed, working memory, long-term memory, recognition mem-
ory, verbal fluency, and vocabulary. We found no evidence
whatsoever indicating that FM patients showed decreased
performance across the 3 testing blocks, although they did
consistently show deficits in working memory and long-term
memory within each block. Thus, we measured consistency of
effort and found it to be unchanging for FM patients as well as
for young and old adults across a 2-hour period.
These two combined findings suggest a high/sustained
level of motivation in FM patients in this study and no
response bias toward poor performance, since performance
was excellent on some cognitive tasks but not on others. The
data are more suggestive of frontal and/or hippocampal dys-
function than they are of motivational deficits. We are actively
pursuing studies to investigate neural mechanisms underlying
the observed deficits.
Denise C. Park, PhD
Jennifer Glass, PhD
Leslie Crofford, MD
University of Michigan
Ann Arbor, MI
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